Drug-induced tyrosine phosphorylation of JAK2 and Src attenuated EGFR and STAT3 tyrosine phosphorylation, but EGFR tyrosine kinase inhibitor therapy (gefitinib) suppressed STAT3 phosphorylation in HCT116 colon cancer cells without influencing JAK2 or Src phosphorylation [62]. This evidence concerns the gene STAT3 and malignant colon neoplasm.